Novel 4,4-bis(trifluoromethyl) imidazolines as stereospecific and orally active acyl CoA: Cholesterol acyltransferase (ACAT) inhibitors and antihypercholesterolemic agents

George A. Boswell; Hui Yin Li; Indawari Delucca; Jeffrey T. Billheimer; Spencer Drummond; Peter J. Gillies; Candy Robinson

doi:10.1016/0960-894X(96)00137-0

Novel 4,4-bis(trifluoromethyl) imidazolines as stereospecific and orally active acyl CoA: Cholesterol acyltransferase (ACAT) inhibitors and antihypercholesterolemic agents

George A. Boswell, Hui Yin Li, Indawari Delucca, Jeffrey T. Billheimer, Spencer Drummond, Peter J. Gillies, Candy Robinson

Research output: Contribution to journal › Article › peer-review

9 Scopus citations

Abstract

A new class of very potent, systemically-active ACAT inhibitors based on a 4,4-bis(trifluoromethyl)imidazoline ring has been discovered. Compound 6 and its R-enantiomer 6a exhibited very potent oral activities in lowering the serum cholesterol in the animals.

Original language	English (US)
Pages (from-to)	885-888
Number of pages	4
Journal	Bioorganic and Medicinal Chemistry Letters
Volume	6
Issue number	7
DOIs	https://doi.org/10.1016/0960-894X(96)00137-0
State	Published - Apr 9 1996
Externally published	Yes

All Science Journal Classification (ASJC) codes

Biochemistry
Molecular Medicine
Molecular Biology
Pharmaceutical Science
Drug Discovery
Clinical Biochemistry
Organic Chemistry

Access to Document

10.1016/0960-894X(96)00137-0

Cite this

Boswell, G. A., Li, H. Y., Delucca, I., Billheimer, J. T., Drummond, S., Gillies, P. J., & Robinson, C. (1996). Novel 4,4-bis(trifluoromethyl) imidazolines as stereospecific and orally active acyl CoA: Cholesterol acyltransferase (ACAT) inhibitors and antihypercholesterolemic agents. Bioorganic and Medicinal Chemistry Letters, 6(7), 885-888. https://doi.org/10.1016/0960-894X(96)00137-0

@article{201b13d15e1f435994a4f235fc61ba82,

title = "Novel 4,4-bis(trifluoromethyl) imidazolines as stereospecific and orally active acyl CoA: Cholesterol acyltransferase (ACAT) inhibitors and antihypercholesterolemic agents",

abstract = "A new class of very potent, systemically-active ACAT inhibitors based on a 4,4-bis(trifluoromethyl)imidazoline ring has been discovered. Compound 6 and its R-enantiomer 6a exhibited very potent oral activities in lowering the serum cholesterol in the animals.",

author = "Boswell, {George A.} and Li, {Hui Yin} and Indawari Delucca and Billheimer, {Jeffrey T.} and Spencer Drummond and Gillies, {Peter J.} and Candy Robinson",

year = "1996",

month = apr,

day = "9",

doi = "10.1016/0960-894X(96)00137-0",

language = "English (US)",

volume = "6",

pages = "885--888",

journal = "Bioorganic and Medicinal Chemistry Letters",

issn = "0960-894X",

publisher = "Elsevier Ltd",

number = "7",

}

Boswell, GA, Li, HY, Delucca, I, Billheimer, JT, Drummond, S, Gillies, PJ & Robinson, C 1996, 'Novel 4,4-bis(trifluoromethyl) imidazolines as stereospecific and orally active acyl CoA: Cholesterol acyltransferase (ACAT) inhibitors and antihypercholesterolemic agents', Bioorganic and Medicinal Chemistry Letters, vol. 6, no. 7, pp. 885-888. https://doi.org/10.1016/0960-894X(96)00137-0

Novel 4,4-bis(trifluoromethyl) imidazolines as stereospecific and orally active acyl CoA: Cholesterol acyltransferase (ACAT) inhibitors and antihypercholesterolemic agents. / Boswell, George A.; Li, Hui Yin; Delucca, Indawari et al.
In: Bioorganic and Medicinal Chemistry Letters, Vol. 6, No. 7, 09.04.1996, p. 885-888.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Novel 4,4-bis(trifluoromethyl) imidazolines as stereospecific and orally active acyl CoA

T2 - Cholesterol acyltransferase (ACAT) inhibitors and antihypercholesterolemic agents

AU - Boswell, George A.

AU - Li, Hui Yin

AU - Delucca, Indawari

AU - Billheimer, Jeffrey T.

AU - Drummond, Spencer

AU - Gillies, Peter J.

AU - Robinson, Candy

PY - 1996/4/9

Y1 - 1996/4/9

N2 - A new class of very potent, systemically-active ACAT inhibitors based on a 4,4-bis(trifluoromethyl)imidazoline ring has been discovered. Compound 6 and its R-enantiomer 6a exhibited very potent oral activities in lowering the serum cholesterol in the animals.

AB - A new class of very potent, systemically-active ACAT inhibitors based on a 4,4-bis(trifluoromethyl)imidazoline ring has been discovered. Compound 6 and its R-enantiomer 6a exhibited very potent oral activities in lowering the serum cholesterol in the animals.

UR - http://www.scopus.com/inward/record.url?scp=0029921270&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029921270&partnerID=8YFLogxK

U2 - 10.1016/0960-894X(96)00137-0

DO - 10.1016/0960-894X(96)00137-0

M3 - Article

AN - SCOPUS:0029921270

SN - 0960-894X

VL - 6

SP - 885

EP - 888

JO - Bioorganic and Medicinal Chemistry Letters

JF - Bioorganic and Medicinal Chemistry Letters

IS - 7

ER -

Novel 4,4-bis(trifluoromethyl) imidazolines as stereospecific and orally active acyl CoA: Cholesterol acyltransferase (ACAT) inhibitors and antihypercholesterolemic agents

Abstract

All Science Journal Classification (ASJC) codes

Access to Document

Other files and links

Fingerprint

Cite this